But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
ApexOnco Front Page
Recent articles
The private biotech adds another asset to J&J’s prostate cancer pipeline.
Some big deals in the second quarter have raised hopes that takeouts are back.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Regeneron is facing two FDA decisions for its T-cell engagers.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Adverse events will be closely watched when full data are reported.
